Cellectar Biosciences (CLRB)
NASDAQ:CLRB
Top Page
Cellectar Biosciences
(NASDAQ:CLRB)
Select Model
Select Model
Rating:43Neutral
Price Target:
$3.00
▼(-8.81% Downside)
Action:ReiteratedDate:03/05/26
The score is held down primarily by weak financial performance (no revenue, ongoing losses and cash burn with financing risk) and bearish technicals (below key moving averages with negative MACD). The latest earnings call adds some offset from regulatory/clinical progress and improved cost structure, but valuation remains constrained by negative earnings and no dividend support.
Positive Factors
Regulatory Progress
Formal EMA alignment plus Breakthrough (FDA) and PRIME (EU) designations and a completed 12‑month pivotal follow‑up materially de‑risk the approval pathway. These durable regulatory advantages improve the probability and speed of conditional approvals, strengthen partner interest, and meaningfully raise commercialization prospects over the next 2–3 years.
Negative Factors
No Revenue and Persistent Losses
The company remains a pre‑commercial, loss‑making operation with no product revenue to offset R&D and G&A. This structural lack of operating cash generation means long‑term viability depends on successful approvals, partnerships, or repeated financing rounds, increasing dilution and execution pressure on management to convert programs to revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Progress
Formal EMA alignment plus Breakthrough (FDA) and PRIME (EU) designations and a completed 12‑month pivotal follow‑up materially de‑risk the approval pathway. These durable regulatory advantages improve the probability and speed of conditional approvals, strengthen partner interest, and meaningfully raise commercialization prospects over the next 2–3 years.
Read all positive factors
Cellectar Biosciences (CLRB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.70M
Dividend YieldN/A
Average Volume (3M)105.19K
Price to Earnings (P/E)―
Beta (1Y)1.09
Revenue GrowthN/A
EPS Growth79.31%
CountryUS
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.65
Shares Outstanding4,240,129
10 Day Avg. Volume157,484
30 Day Avg. Volume105,193
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.78
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market Cap-0.34
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit39.08
Enterprise Value/Ebitda0.18
Forecast
1Y Price Target
$12.00Price Target Upside264.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.54
Revenue Forecast (FY)N/A
Cellectar Biosciences Business Overview & Revenue Model
Company Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131...
How the Company Makes Money
Cellectar Biosciences is a clinical-stage company and, based on publicly available information, has not been described as generating material recurring revenue from commercial product sales. As a result, its ability to fund operations has primaril...
Cellectar Biosciences Earnings Call Summary
Earnings Call Date:Mar 04, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Neutral
The call emphasized significant strategic and clinical progress—regulatory alignment with EMA, Breakthrough/PRIME designations, full 12‑month follow-up on the pivotal dataset, initiation of CLR125 Phase 1b, strengthened IP and isotope supply, and material reductions in operating expenses that improved the company’s net loss profile. Offsetting these positives are a constrained cash position (cash runway only into 2026), the need for additional capital to initiate certain programs (notably CLR225) and execute confirmatory trials, reliance on enrollment and regulatory timing for near‑term milestones, and a substantial drop in other (non‑cash) income. Overall, the company made meaningful de‑risking and value-creation moves but faces near-term financing and execution risks.Positive Updates
Regulatory Progress for Lead Asset (iapocine I-131)
Achieved regulatory alignment with EMA (SAWP guidance) and plan to submit a conditional marketing authorization (CMA) in 2026 with potential European commercialization as early as 2027. FDA engagement supports pursuing an NDA under the accelerated approval pathway; Breakthrough Therapy designation in the U.S. and PRIME designation in the EU. Full 12-month follow-up on CLOVER‑WaM dataset now collected, strengthening the dossier for both accelerated approval and confirmatory trial design.
Negative Updates
Tight Cash Position and Near-Term Funding Needs
Cash and cash equivalents decreased to $13.2M as of 12/31/2025 from $23.3M a year earlier (down ~$10.1M, ≈43.3% decrease). Management expects cash to fund budgeted operations only into 2026, creating a near-term need for additional capital to support confirmatory Phase 3, CLR225 initiation, and broader development/commercial activities.
Read all updates
Q4-2025 Updates
Positive
Negative
Regulatory Progress for Lead Asset (iapocine I-131)
Achieved regulatory alignment with EMA (SAWP guidance) and plan to submit a conditional marketing authorization (CMA) in 2026 with potential European commercialization as early as 2027. FDA engagement supports pursuing an NDA under the accelerated approval pathway; Breakthrough Therapy designation in the U.S. and PRIME designation in the EU. Full 12-month follow-up on CLOVER‑WaM dataset now collected, strengthening the dossier for both accelerated approval and confirmatory trial design.
Read all positive updates
Company Guidance
Management gave concrete near‑term guidance: they plan to submit a conditional marketing authorization (CMA) to the EMA for their lead I‑131 radiotherapeutic for Waldenström’s macroglobulinemia in 2026 (targeting potential EU approval as early as 2027) and will pursue FDA accelerated approval under Breakthrough Therapy designation using the CLOVER‑WaM dataset with full 12‑month follow‑up available in early 2026; the FDA requires a confirmatory Phase 3 in a post‑BTKi second‑line population to be initiated and enrolling at submission, management expects to file the NDA ~1–2 months after starting that trial and anticipates the six‑month accelerated review (i.e., an FDA response roughly 7–9 months after study start) assuming about 10% enrollment by that time. They raised ~$15.2M in 2025 (including $5.8M in Q4), ended 12/31/2025 with $13.2M cash (vs. $23.3M at 12/31/2024) and expect cash to fund operations into 2026; FY‑2025 net loss was $21.8M ($8.35/share) vs $44.6M in 2024, R&D and G&A were each ~ $11.5M in 2025 (vs. $26.6M R&D and $25.6M G&A in 2024), and other income was ~$1.1M (vs. $7.3M). Operational milestones include initiating the CLR125 Phase 1b in TNBC (early/interim dosimetry, safety and preliminary efficacy data expected mid‑2026), completing IND‑enabling work for CLR225 pending funding, securing supply partnerships for Ac‑225 and At‑211, expanding global patent coverage, and expecting multiple value‑creating readouts through 2026.Cellectar Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -213.60K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -22.77M | -51.49M | -38.77M | -28.67M | -23.98M |
| Net Income | -21.79M | -44.58M | -42.77M | -31.79M | -24.12M |
Balance Sheet | |||||
| Total Assets | 14.98M | 25.47M | 12.08M | 21.59M | 37.20M |
| Cash, Cash Equivalents and Short-Term Investments | 13.20M | 23.29M | 9.56M | 19.87M | 35.70M |
| Total Debt | 409.59K | 494.00K | 552.98K | 603.83K | 301.74K |
| Total Liabilities | 5.06M | 11.18M | 25.85M | 12.05M | 4.16M |
| Stockholders Equity | 9.92M | 14.29M | -13.78M | 9.54M | 33.05M |
Cash Flow | |||||
| Free Cash Flow | -23.12M | -47.69M | -33.24M | -25.45M | -22.71M |
| Operating Cash Flow | -23.12M | -47.58M | -32.38M | -25.22M | -22.57M |
| Investing Cash Flow | -5.88K | -104.19K | -864.04K | -225.97K | -141.36K |
| Financing Cash Flow | 13.03M | 61.41M | 22.94M | 9.61M | 1.25M |
Cellectar Biosciences Technical Analysis
Neutral
3.29
Price Trends
3.06
Negative
3.18
Negative
4.06
Negative
Market Momentum
-0.13
Positive
43.97
Neutral
45.65
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLRB, the sentiment is Neutral. The current price of 3.29 is above the 20-day moving average (MA) of 2.94, above the 50-day MA of 3.06, and below the 200-day MA of 4.06, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 43.97 is Neutral, neither overbought nor oversold. The STOCH value of 45.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CLRB.
Cellectar Biosciences Risk Analysis
Cellectar Biosciences disclosed 42 risk factors in its most recent earnings report. Cellectar Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cellectar Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $113.81M | -6.36 | -119.19% | ― | -90.43% | -382.07% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $234.55M | -0.12 | 506.72% | ― | ― | -323.61% | |
43 Neutral | $11.70M | -0.59 | -248.91% | ― | ― | 79.31% | |
41 Neutral | $7.25M | -0.33 | ― | ― | ― | ― | |
41 Neutral | $7.44M | -0.33 | -925.11% | ― | ― | ― |
* Healthcare Sector Average
CLRB
Cellectar Biosciences
2.76
-4.61
-62.55%
CANF
Can-Fite BioPharma
3.08
-25.12
-89.08%
NERV
Minerva Neurosciences
5.42
4.08
304.48%
ATON
AlphaTON Capital
0.32
-4.70
-93.69%
EQ
Equillium
1.80
1.33
282.98%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.